PULM (Pulmatrix Corp) Forward Price-to-Revenue Multiple
The modeled P/S of Pulmatrix, Inc. (PULM) demonstrates market expectations, where the value of 46.50 reflects this status. This trend is based on the implementation of laboratory automation for molecular analysis. Prospects depend on the efficiency of lung drug delivery via iSPERSE. Growth is driven by PUR1900 trials and the search for partners for cystic fibrosis therapy, which determines the investment attractiveness of this biotech.
Metric breakdowns and analytics for Pulmatrix Corporation (PULM)
- market price and analyst price targets:
- business market valuation indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Pulmatrix, Inc.|PULM - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Pulmatrix, Inc.|PULM - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Pulmatrix Corporation|PULM - Company Long-Term Loans and Borrowings|Company Short-Term Debts Pulmatrix|Quick Liquidity Indicator pulmatrix.com
- business earnings and investment ratios data:
PULM - Company Profit|Future Profit Pulmatrix, Inc.|PULM - Company Value to Net Income|Forward P/E Multiple Pulmatrix Corp|PULM - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pulmatrix Corporation|PULM - Operating profit before amortization|Net earnings per share (EPS TTM) Pulmatrix|PULM - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months pulmatrix.com|PULM - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Pulmatrix, Inc.
- sales revenue and business income indicators:
General company analysis:PULM (Pulmatrix)
The robotization of precision powder engineering at Pulmatrix, Inc. (PULM) minimizes manual labor, creating a foundation for revenue scaling. The ratio of market capitalization to projected sales allows for a valuation of this technological advantage, preventing overpayment based on unjustified optimism. By analyzing the forward P/S multiple, an investor can identify arbitrage gaps and acquire shares at a discount during maximum price drawdowns relative to expected growth.
Key competitors
Price-to-Projected Revenue Ratio Haleon HLN|KVUE (Kenvue Inc) - Future Price to Revenue|VRNA: Forward Price-to-Revenue Multiple|MENS - Forward P/S Multiple|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|AMRX (amneal.com) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Perrigo|Forward Price-to-Revenue Multiple Alvotech S.A. (ALVO)|Forward P/S Multiple LQDA|Forward P/S Multiple Galapagos Corp (GLPG)|ANI Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio MNKD (mannkindcorp.com)|AMPH - Price-to-Projected Revenue Ratio|Forward Price to Sales PCRX (Pacira Pharmaceuticals)|SPRY: Forward P/S Multiple|TBPH - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AQST|Market Cap to Projected Revenue SCPH (scPharma)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharma) - Forward Price to Sales|Forward P/S Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST - Price-to-Projected Revenue Ratio|EXOZ (invizyne.com) - Market Cap to Projected Revenue|ORMP: Forward P/S Multiple|Forward Price-to-Revenue Multiple Entera Bio|Forward Price-to-Revenue Multiple HYFT|ABVC BioPharma, Inc (ABVC) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals (CPIX)|QNTM: Future Price to Revenue|FibroGen - Forward Price-to-Revenue Multiple|Forward P/S Multiple Telomir Pharmaceuticals Inc TELO|RANI - Price-to-Projected Revenue Ratio|SNYR: Price-to-Projected Revenue Ratio|rallybio.com (RLYB) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Lexaria Bioscience Corp.|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Aptorum - Future Price to Revenue|Forward P/S Multiple LYRA|IBO (Impact BioMedical, Inc.) - Forward Price to Sales|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Forward P/S Multiple cbdMD Inc. YCBD|PRFX - Price-to-Projected Revenue Ratio|Forward Price to Sales CYTO (Altamira Therapeutics)|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple OptiNose Corp|PIRS (Pieris Pharmaceuticals) - Forward P/S Multiple|Forward P/S Multiple procapsgroup.com|Forward Price-to-Revenue Multiple PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding Group) - Forward Price to Sales|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|TFF Pharmaceuticals, Inc (TFFP) - Market Cap to Future Revenue Ratio
